Donor Lymphocyte Infusion

This policy covers donor lymphocyte infusion (DLI)—infusion of donor-derived T cells—to prevent or treat relapse and to convert mixed to full donor chimerism after allogeneic hematopoietic stem cell transplantation for hematologic malignancies (eg, CML, AML, ALL, lymphomas, multiple myeloma, MDS), including pre‑emptive use for MRD. DLI is limited to post‑allogeneic (not autologous) transplants, is contraindicated with full donor or total host chimerism and active acute GvHD ≥ grade 2, carries significant risks of GvHD and marrow aplasia, and ex vivo manipulation or genetic modification of DLI products is investigational.

"Donor lymphocyte infusion (DLI) to decrease risk of relapse following allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies."

Sign up to see full coverage criteria, indications, and limitations.